Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

Shunyou Wang,1,2 Jing Gao,1,2 Qunying Lei,1,2 Nora Rozengurt,3 Colin Pritchard,4 Jing Jiao,1,2 George V. Thomas,3 Gang Li,1,2 Pradip Roy-Burman,5 Peter S. Nelson,4 Xin Liu,2,3 and Hong Wu1,2,*

1Howard Hughes Medical Institute
2Department of Molecular and Medical Pharmacology
3Department of Pathology and Laboratory Medicine
University of California Los Angeles School of Medicine, Los Angeles, California 90095
4Division of Human Biology Mailstop D4-100, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, Seattle, Washington 98109
5Department of Pathology, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, Los Angeles, California 90033
*Correspondence: hwu@mednet.ucla.edu

Summary

The murine Pten prostate cancer model described in this study recapitulates the disease progression seen in humans: initiation of prostate cancer with prostatic intraepithelial neoplasia (PIN), followed by progression to invasive adenocarcinoma, and subsequent metastasis with defined kinetics. Furthermore, while Pten null prostate cancers regress after androgen ablation, they are capable of proliferating in the absence of androgen. Global assessment of molecular changes caused by homozygous Pten deletion identified key genes known to be relevant to human prostate cancer, including those “signature” genes associated with human cancer metastasis. This murine prostate cancer model provides a unique tool for both exploring the molecular mechanism underlying prostate cancer and for development of new targeted therapies.

Introduction

Prostate cancer is the most common malignancy in men and the second leading cause of male cancer-related deaths in the Western world. Its development proceeds through a series of defined states, including prostatic intraepithelial neoplasia (PIN), prostate cancer in situ, invasive and metastatic cancer. The standard therapies include androgen ablation that initially relapse and develop into hormone refractory prostate cancer (HRPC) (Denis and Murphy, 1993; Landis et al., 1999).

The PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor gene is one of the most frequently mutated/deleted genes in various human cancers (Bose et al., 2002; Deocampo et al., 2003; Sun et al., 2002; Wang et al., 2003; Zhou et al., 2002). Germline mutations in the PTEN gene have been associated with Cowden syndrome and related diseases in which patients develop hyperplastic lesions (hamartomas) in multiple organs with increased risks of malignant transformation (Dahia, 2000; Liaw et al., 1997; Marsh et al., 1999). PTEN alteration is strongly implicated in prostate cancer development. PTEN deletions and/or mutations are found in 30% of primary prostate cancers (Dahia, 2000; Sellers and Sawyers, 2002) and 63% of metastatic prostate tissue samples (Suzuki et al., 1998b), placing PTEN mutation among the most common genetic alterations reported in human prostate cancers.

PTEN-controlled signaling pathways are frequently altered in human prostate cancers, making them promising targets for therapeutic strategies (DeMarzo et al., 2003; Sellers and Sawyers, 2002; Vivanco and Sawyers, 2002). The major function of the tumor suppressor PTEN relies on its phosphatase activity and subsequent antagonism of the PI3K/AKT pathway (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000; Maehama et al., 2001). Loss of PTEN function, either in murine embryonic stem cells or in human cancer cell lines, results in accumulation of PIP3 and activation of its downstream effectors, such as AKT/PKB (Stambolic et al., 1998; Sun et al., 1999; Wu et al., 1998). As a serine/threonine protein kinase, AKT functions by phosphorylating key intermediate signaling molecules, such as

SIGNIFICANCE

Cancer of the prostate is the most common malignancy in men. Study of the biology of prostate cancer and the development of new therapies have been hampered by a lack of appropriate animal models designed to mimic genetic alterations that are frequently found in human prostate cancer. The Pten conditional knockout mice characterized in this study fulfilled this demand. Since the initiating oncogenic event is androgen independent, the Pten conditional deletion mice may provide a unique opportunity to address the mechanisms of resistance to androgen ablation therapy. By identifying possible downstream targets of PTEN-controlled prostate tumorigenesis, our findings suggest that studying genetically defined mouse models can yield valuable molecular insights that impact on human cancer research.
glycogen synthase kinase-3 (GSK3), BAD, Caspase 9, and IκB, leading to increased cell metabolism, cell growth, and cell survival (Di Cristofano and Pandolfi, 2000; Hanahan and Weinberg, 2000; Vivanco and Sawyers, 2002). Recent studies also suggest that PTEN may function through AKT-independent mechanisms (Freeman et al., 2003; Gao et al., 2000; Weng et al., 2001).

Inactivation of Pten in mice models has confirmed PTEN as a bona fide tumor suppressor. Pten 


1/2 mice showed a broad spectrum of spontaneous tumor development, with a bias toward organs such as large and small intestines, lymphoid, mammary, thyroid, endometrial, and adrenal glands (Di Cristofano et al., 1998; Podsypanina et al., 1999; Stambolic et al., 2000; Suzuki et al., 1998a). Since homozygous deletion of Pten causes early embryonic lethality, previous studies for prostate cancers caused by Pten deletion were invariably using Pten heterozygous mice. Different rates of prostatic hyperplasia and cancer have also been reported in the above studies. Our recent study demonstrated that Pten 


1/2 males on a Balb/c/129 genetic background developed lesions (PIN) with near 100% penetrance (D. Freeman et al., submitted). However, the latency for PIN formation is rather long, approximately 10 months, and these PIN lesions never progress to metastatic disease. These results raised several questions: (1) Does the rate of Pten LOH determine the onset of prostate cancer initiation? (2) Is Pten LOH required for prostate tumor progression? and (3) What genetic changes, in addition to Pten deletion, are necessary for prostate cancer progression and metastasis?

Mice with combined deletion of Pten and other tumor suppressor genes, as possible “second hits,” have been generated. Pten 


1/2;p27 


1/2 compound mutant mice display an increased incidence of high-grade PIN but not prostate cancer (Kim et al., 2002). Similarly, Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of PIN associated with Pten heterozygosity (You et al., 2002). However, no metastatic prostate cancers were reported in these models (Di Cristofano et al., 2001; Kim et al., 2002; You et al., 2002). Pten heterozygous mice were also crossed with the well-characterized TRAMP model (Greenberg et al., 1995). Pten LOH significantly shortened the average life span of TRAMP mice from 245 days to 159 days (Kwabi-Addo et al., 2001). More recently, the MPAKT model was created that expressed constitutively activated AKT in mouse prostate epithelial cells (Majumder et al., 2003). The MPAKT mice develop PIN lesions in the ventral prostate with prominent bladder obstruction. No progression to metastatic prostate cancer was reported (Majumder et al., 2003).

To assess whether Pten homozygous deletion is critical for prostate cancer progression, we generated Pten 


1/2;Cre 


mice to achieve prostate-specific Pten deletion. Our studies demonstrated that Pten LOH leads to a significant shortened latency of PIN formation and results in prostate cancer progression to a metastatic stage, mimicking the disease progression seen in humans. The Pten conditional prostate deletion mice also provide a unique opportunity to address the mechanism of resistance to androgen ablation therapy in a genetically defined model where the initiating oncogenic event is not androgen dependent. Our characterization of the Pten model by expression profiling has further indicated that the Pten model has many additional similarities to human prostate cancers.

Results

Cre-mediated Pten homozygous deletion and upregulated AKT activity

To achieve Pten prostate-specific deletion, we crossed Pten 


1/2;Cre mice (Lescce et al., 2002) to the ARRA2Probasin-Cre transgenic line, PB-Cre4, in which the Cre recombinase is under the control of a modified rat prostate-specific probasin (PB) promoter (Wu et al., 2001). By crossing PB-Cre4 to a conditional reporter mouse R26R, the original report indicated that Cre expression is specific for prostatic epithelial cells. However, its expression levels vary from lobe to lobe: highest in the lateral lobe (LP), followed by the ventral (VP), dorsal (DP), and least in anterior lobes (AP) (Wu et al., 2001). Since Cre-mediated recombination event is a unidirectional process, cells with Cre-mediated gene deletion are likely to increase and accumulate over time. Indeed, a recent follow up study indicated that Cre-mediated recombination events increased to near 100% in LP/VP/DP at the age of 8 months (Powell et al., 2003).

To confirm prostate-specific Pten deletion, the urogenital organs as well as other tissues from Pten 


1/2;Cre mice at the age of 9 and 25 weeks were carefully dissected, and the status of Pten deletion was examined by sensitive PCR and immunohistochemistry (IHC) analyses. PCR analysis of 9-week-old Pten 


1/2;PB-Cre4 mice showed Pten deletion, as indicated by excision of the exon 5 of Pten gene (Pten 


1/2), specific to the prostate gland. Except trace amount of Pten exon 5 deletion in the seminal vesicle, all the other tissues tested showed no detectable recombination activity (Figure 1A), consistent with the previous report (Wu et al., 2001). Double immunofluorescent analysis demonstrated that PTEN is highly expressed in cytoplasm and less so in the nucleus of prostatic epithelial cells lining the prostatic acini as well as the stromal cells surrounding the acini (Figure 1B, left panel; Pten in red). Deletion efficiencies of the Pten floxed alleles in different lobes were similar to the Cre expression pattern reported previously: PTEN immunostaining is significantly reduced in the lateral and ventral lobes but only lost or diminished in a subset of the cells in the dorsal and anterior lobes of 4-week-old Pten 


1/2;PB-Cre4 mice (Supplemental Figure S1 at http://www.cancercell.org/cgi/content/full/4/3/209/DC1, LP from WT and mutant mice are shown here). By 9 weeks, a majority of the cells in the epithelial compartment of DLP and VP show loss of PTEN immunostaining, and approximately 40%–60% cells in the AP are Pten null (Figure 1B, right panels; Pten in red). Furthermore, Pten immunostaining in the stromal compartment remains positive, further confirming Pten epithelial-specific deletion.

As a result of Pten loss, the AKT serine/threonine kinase, one of the primary targets of the PTEN-controlled signaling pathway, is activated. Thus, AKT phosphorylation and plasma membrane localization can serve as reliable indicators for Pten loss. AKT phosphorylation is rarely detectable in the WT prostate (Figure 1B, left panels; P-AKT in green; also see Supplemental Figure S1B on Cancer Cell website) but is highly expressed in Pten null cells, especially at the plasma membrane of the DLP and VP (Figure 1B, right panels; also see Supplemental Figure S1F). Pten null, AKT-activated cells were also larger than their WT or heterozygous control cells (Supplemental Figure S1, insets), consistent with the role of PTEN in controlling cell size (Backman et al., 2002; Groszer et al., 2001).
**Pten homozygous deletion shortens latency for mPIN formation**

To determine whether deletion of both alleles at the *Pten* locus, or loss of heterozygosity (LOH), is required for prostate cancer initiation and progression, we examined cohorts of littermates, WT (*Pten<sup>lox/lox</sup>;PB-Cre<sup>4</sup>), heterozygous (*Pten<sup>lox</sup>;PB-Cre<sup>4</sup>), and homozygous (*Pten<sup>lox/lox</sup>;PB-Cre<sup>4</sup>) for *Pten* prostate-spe-
cific deletion from 4 to 29 weeks. To avoid potential variations contributed by genetic background, only mice from the F2 generation were used for studies described below.

Deletion of both alleles of *Pten* led to progressively enlarged prostate glands. Histological analysis indicated that from 4 weeks on, the prostates of the mutant mice developed multifocal hyperplasia. These were initially observed in the dorsolateral and ventral lobes and subsequently involved the anterior lobes as well, consistent with the efficiency of Cre-mediated *Pten* deletion. Figure 2A shows a comparison of dorsolateral lobes from WT and their *Pten* null littermates from 4 to 12 weeks. Epithelial hyperplasia, characterized by increased number of cells (without cellular atypia), is seen by 4 weeks of age (Figure 2A, a compared to b). By 6 weeks of age, these mice develop murine PIN (mPIN). mPIN is the proliferation of atypical epithelial cells within pre-existing prostatic ductules and acini (Figure 2Ad and supplemental Figure S2A on Cancer Cell website). This proliferation results in stratification of the epithelial layer, giving rise to distinctive architectural features, to include cribriform, tufting, or micropapillary growth patterns (Figure 2Ad). Cytological atypia is characterized by nuclear enlargement, nuclear contour irregularity, hyperchromatism, and prominent nucleoli accompanied by the inversion of the nuclear to cytoplasmic ratio (Figure 2Ac compared to 2Ad; arrows point to atypical cells). One hundred percent of the homozygous mice developed mPIN at 6 weeks (Table 1). Thus, homozygous *Pten* deletion significantly shortened the latency for mPIN formation from 8–10 months in heterozygous to 1.5 months in homozygous conditional knockouts. Significantly, *Pten* null mPIN lesions progress to invasive and metastatic cancers (see below). These results demonstrate that (1) homozygous PTEN loss alone is sufficient for prostate cancer initiation; and (2) *Pten* LOH is a rate-limiting step for prostate cancer initiation and progression.

**Homozygous Pten deletion leads to invasive adenocarcinoma**

While mice with heterozygous *Pten* deletion develop mPIN late in their lives (12–16 months, D. Freeman et al., submitted), mice with homozygous *Pten* deletion develop invasive adenocarcinoma by 9 weeks of age. Adenocarcinoma was seen in all lobes. Figure 2A compares dorsolateral lobes of WT and mutant prostate at 9 and 12 weeks. From 9 weeks onward, we have observed the extension of malignant cells, either as individual cells or as nests of acini. Initially extending through the basement membrane (Supplemental Figure S2, right panel) and subsequently through the fibromuscular layer, as shown by the loss of SMA immunostaining (Supplemental Figure S2, middle panel), the cancer cells then invaded the stroma (Figure 2Af). This in turn induces both an inflammatory and a desmoplastic response (Supplemental Figure S2, right panel). This desmoplastic response is characterized by focal stromal cellularity, found in association with the invasive cancer. These prostate cancer cells show increased proliferation compared to the WT controls, as indicated by their Ki67-positive staining (Figure 2B, left panels).

Prostate epithelium includes basal cells, luminal cells, and neuroendocrine cells. Transgenic mice overexpressing the oncogenic SV40 T antigen (Garabedian et al., 1998; Greenberg et al., 1995; Kasper et al., 1998; Masumori et al., 2001) develop both adenocarcinoma and neuroendocrine carcinoma. To define the origin of *Pten* null prostate cancers in the current model, we performed immunohistochemical analyses. Neuroendocrine...
Figure 2. Homozygous Pten deletion leads to adenocarcinoma formation

A: A comparison of pathological phenotype of 4- to 12-week-old Pten<sup>+/+</sup>;Cre<sup>+</sup> (Mut) mice and their Pten<sup>+/+</sup>;Cre<sup>-</sup> (WT) littermate controls. Only dorsolateral lobes are shown here. Epithelial hyperplasia is seen by 4 week of age in the Pten null mice (a compared to b), mPIN is evident by 6 week (c compared to d; arrows point to cells with atypia), and this progresses to invasive adenocarcinoma by 9 week of age (compare e and g to f and h).

B: Immunohistochemical analyses indicate that Pten null prostate cancer cells are proliferative, as indicated by Ki67-positive immunostaining (right panels), and are derived from secretory epithelium (AR<sup>+</sup>, left panels; synaptophysin-negative, middle panels). Middle left panel, high-power image shows synaptophysin-positive neuroendocrine cells in the mutant prostate (arrow).

cells in normal and neoplastic prostate are devoid of androgen receptor (AR) and are positive for chromogranin A and synaptophysin (SNP) (for review, see Sciarra et al., 2003). As shown in Figure 2B, Pten null cancer cells were AR positive (Figure 2B, left panels), a hallmark of secretory epithelium, but were negative for the neuroendocrine cell marker synaptophysin (Figure 2B, middle panels). Thus, Pten deletion results in an adenocarcinoma, i.e., epithelial origin, differing from T antigen transgenic mice in which tumors are of neuroendocrine origin.

**Homozygous Pten deletion leads to metastatic prostate cancers**

Similar to the progression of human prostate cancers, Pten null prostate cancers also progress from mPIN to invasive adenocarcinoma, then to metastatic carcinoma with precisely defined kinetics. We have observed lymphovascular invasion in the Pten conditional knockout mice from 12 weeks of age (present in 5 of 11 mice, Table 1; Figures 3Aa, 3Ab, 3Ae, and 3Af) with subsequent seeding of the subcapsular sinuidal regions of draining lymph nodes (2 of 11 mice; Figures 3Ac and 3Ag; also see supplemental Figure S3) and pulmonary alveolar spaces (3 of 11 mice; Figures 3Ad and 3Ah). The metastatic tumor cells in the lung alveolar space remain AR positive (Figure 3B, left panel) and are negative for PTEN immunostaining (Figure 3B, right panel).

**Table 1. Phenotypes associated with Pten prostate-specific deletion**

<table>
<thead>
<tr>
<th>Age (weeks)</th>
<th>WT/Het</th>
<th>Homozygous</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>2/2 normal</td>
<td>4/4 hyperplasia</td>
</tr>
<tr>
<td>6</td>
<td>15/15 normal</td>
<td>9/9 mPIN</td>
</tr>
<tr>
<td>9-29</td>
<td>31/31 normal</td>
<td>16/16 invasive carcinoma</td>
</tr>
<tr>
<td>12-29</td>
<td>5/11 with metastasis</td>
<td>3/14 were died</td>
</tr>
</tbody>
</table>
In response to androgen withdrawal, the AR-positive prostatic epithelium undergoes increased apoptosis, as indicated by dramatically increased TUNEL-positive cells, which results in a reduction of prostate volume following castration (Supplemental Figures S4 and S5 on Cancer Cell website). In the WT control prostate, cell death can be easily detected 3 days after castration and peaks around 6 days (Figure 4A, TUNEL-positive cells in brown; blue bars on the right panel show quantification). Even though PTEN is known for its role in negatively regulating apoptosis (Di Cristofano et al., 1998), quantitative analysis indicates that there is almost 10 times increase of apoptotic cells in the Pten null prostate 3 days post-castration compared with intact animal (Figure 4A, red bars; p < 0.005), suggesting that the survival of Pten null prostate cancer cells is androgen dependent. The percentage of apoptotic cell drops when the measurement is taken at 6 days post-castration (Figure 4A, p < 0.005), indicating that Pten null prostate cancer cells may adapt to the new condition and exhibit enhanced survival, or the androgen-sensitive population has been gradually depleted.

To test whether mice with Pten null prostate cancer would benefit from androgen ablation therapy, we castrated Pten conditional knockouts at 2.5–4 months when invasive adenocarcinoma has already formed. For intact mice, 3/14 Pten prostate conditional knockouts died by the age of 12–29 weeks (Table 1). In contrast, no lethality is observed in 8/8 castrated Pten null mice aged from 7–10 months, indicating that Pten null prostate cancers do benefit from androgen ablation therapy. However, when these mice were sacrificed 2.5 months after castration, we found that a substantial number of Pten null prostate cancer cells remained (Figure 5). Histological analysis demonstrates that Pten null prostate glands remain 5–10-fold larger when compared to age-matched WT controls (Figure 5, left panels; comparing LP of WT and mutant). Residual invasive adenocarcinoma is clearly evident (Figure 5, lower middle panel; red arrows point to cords of cancerous cells coursing through desmoplastic stroma). This enlargement, at least in part, is due to the higher proliferation index in the Pten null prostate (Figure 4B shows Ki67 staining and quantification (Figure 4B). Surprisingly, the proliferation indexes of Pten null prostate are 17-fold higher than age- and genetic background-matched WT controls at 3 days, as well as 6 days and 10 weeks, after castration and are comparable to the pre-castration stage, suggesting that Pten deletion leads to androgen-independent or semi-independent cell proliferation. Interestingly, while most of the Pten null prostate cancer cells remain AR positive, it exhibits a more diffuse, heterogeneous immunostaining pattern (Figure 5, right panels). The Pten null prostate cancer cells are likely to be sensitive to androgen, as indicated by the higher percentage of TUNEL-positive cells found in Pten null prostate 10 weeks after castration (Figure 4A). Even though the remaining adenocarcinoma in Pten conditional knockouts did not lead to premature death during the short observation period, the knockouts may have the potential, as indicated by their ability to proliferate in the absence of androgen, to develop into HRPC, similar to that of humans, after prolonged castration.

**Gene expression analysis revealed similarities between molecular mechanisms underlying Pten null murine cancers and human prostate cancers**

To provide insights into the molecular events associated with prostate tumorigenesis, we compared gene-expression profiles...
of Pten null prostates with age-matched WT controls using microarray analysis. Our initial studies were focused on animals 26–29 weeks of age since 100% of mutant animals at this stage have already developed invasive adenocarcinoma. Half of the prostate was fast frozen for RNA preparation and the other half was fixed for pathological evaluation. Histological analysis indicated that more than 80% of the Pten null prostate tissue at this stage was composed by microinvasive cancer cells and mPIN and less than 20% by stoma and inflammatory cells (data not shown). Statistical analysis of 10290 mouse genes/ESTs generated a list of 1041 significantly altered genes/ESTs (Table S1 in Supplemental Data). Among them, 579 are upregulated in Pten null cancer and 462 are downregulated, and the top 50 up- and downregulated genes are shown in Figure 6A.

Gene expression changes in the Pten null prostate cancers included orthologs of genes whose expression also changes in human prostate cancers, such as upregulated cyclin A, clusterin, PSCA, S100P, ERG-1, and osteopontin, as well as downregulated Nkx3.1 and myosin heavy chain 11 (Aaltomaa et al., 1999; Bowen et al., 2000; Dhanasekaran et al., 2001; Gu et al., 2000; He et al., 1997; Hotte et al., 2001; Mousses et al., 2002; Ramaswamy et al., 2003; Reiter et al., 1998; Steinberg et al., 1997). The corresponding protein expression levels of selected genes, which are underlined in Figure 6A, were further confirmed by immunohistological staining or Western blot analysis. As shown in Figures 6B and 6C and summarized in Figure 7, some changes, such as Nkx3.1 and clusterin (also see Supplemental Figure S1), are directly associated with homozygous Pten deletion and may be regulated by a PTEN-controlled signaling pathway; other changes are observed during tumor progression, such as PSCA (Figure 6B), or related to metastasis (osteopontin, Z. Song and P.R.-B., personal communication). These later groups may represent the additional genetic alterations associated with prostate cancer development (Figure 7). Clusterin (Steinberg et al., 1997) and osteopontin (Hotte et al., 2002) are secreted molecules and could be used as potential biomarkers for cancer staging and molecular diagnostics.

Recently, molecular signatures of metastatic potential have been found within the bulk cell mass of primary tumors, suggesting that metastasis may be an intrinsic property inherited in the primary cancers (Ramaswamy et al., 2003; van ‘t Veer et al., 2002). Interestingly, among 17 such “signature genes” identified in various human cancers, three genes, namely Co11a1, Co11a2, and Myh11, are also up- or downregulated in our Pten prostate models (Figure 6A, genes are marked with *), consistent with the metastasis potential of Pten prostate cancer cells described in this study. Taken together, our initial characterization of changes in gene expression profiling suggests that the Pten prostate model will be useful to provide insights into the molecular events associated with prostate cancer progres-
Invasive adenocarcinoma remains in the Pten null prostate 2.5 months post-castration. Left panels, H&E stained section show enlarged prostate gland in Pten conditional knockout, as compared to its WT littermate after 2.5 months of castration. Arrows indicate lateral prostate lobes (all images taken at the same magnification). Middle panels, invasive adenocarcinoma in Pten conditional knockout. Note cords of cancerous cells (red arrows) are mixed with reactive stroma. Right panels, AR-positive staining in WT and mutant prostate tissues 10 weeks post-castration. Note AR immunostaining is weaker and more heterogeneously diffused post-castration.

Discussion

Animal models for human prostate cancer

Animal models that mimic genetic alterations and clinical courses of human prostate cancer are at high demand for the study of the molecular mechanisms underlying prostate tumorgenesis and for innovation and validation of new anti-cancer strategies. Currently available models for prostate cancer research include Huggins’ spontaneous canine model, the Dunning and Noble rat models, the prostate organ reconstitute model, and several transgenic mouse models (Powell et al., 2003). Mouse models, created via either transgenic or knockout approaches, are more frequently utilized than the canine or rat models because of their clearly defined genetics and molecular targets. So far, the transgenic adenocarcinoma mouse prostate (TRAMP) is the only mouse prostate cancer model that progresses beyond the PIN lesion. However, this SV40 T antigen transgenic model has high neuroendocrine differentiation potential (Garabedian et al., 1998), a phenotype morphologically and biologically distinct from the adenocarcinomas seen in most human prostate cancers (Powell et al., 2003). The SV40 T antigen model also has the limitation that the oncogene is driven by an androgen-dependent promoter and, therefore, it is not an ideal model for studying the mechanism of androgen independence after androgen ablation. The attempt of genetic inactivation of several classic tumor suppressor genes, such as Rb1, Tp53, and Cdkn1B, has yielded little information regarding their involvement in prostate cancer development. Mice lacking Rb1 are embryonic lethal, and Tp53, Cdkn1B (p27KIP1), or Nkx3.1 deletion either has no effect on prostate cancer development (Tp53 and Cdkn1B) (Powell et al., 2003) or results in only a hyperplasia/dysplasia phenotype in aged animals (Nkx3.1) (Abdulkadir et al., 2002; Bhatia-Gaur et al., 1999; Tanaka et al., 2000).

As summarized in Figure 7, the Pten prostate cancer model mimics the course of human prostate cancer formation: it progresses from hyperplasia to mPIN, then to invasive adenocarcinoma, followed by metastasis. Histologically, the Pten null tumor is derived from secretory epithelium, similar to the origin of the majority of human prostate tumors. Notably, the invasive Pten null prostate cancer cells do respond to androgen ablation, as indicated by increased apoptosis, similar to most human prostate cancers. Even though the survival of Pten null prostate cancer cells is androgen sensitive, their proliferation is not affected by androgen withdrawal. The property of androgen-independent growth observed in Pten null prostate cancers may contribute to hormone-resistant prostate cancer formation. Finally, Pten homozygous deletion leads to gene expression changes seen in human prostate cancers and shares similarities with other human cancers with metastatic potentials. Thus, Pten prostate conditional knockout mice described in this study may serve as a very useful tool for studying the molecular mechanisms underlying prostate cancer metastasis and HRPC formation.
Prostate cancer metastasis

Prostate cancers are known to metastasize; however, so far very little is known regarding the mechanisms governing prostate cancer metastasis (Cher, 2001; Mundy, 2002). The process of metastasis is often regarded as a multistep event, and each event must be successful for the entire process to occur. The successful metastatic cell must leave the primary site, enter and survive in the lymphatic and blood circulatory systems, overcome host defenses, extravasate and grow as a metastatic colony (Fidler and Kripke, 2003). Thus it is believed that the metastatic cell is a rare cell mixed within the heterogenous tumor population. This notion is primarily supported by animal models in which poorly metastatic cell lines can spawn highly metastatic variants after multiple rounds of selection (Clark et al., 2000; Fidler and Kripke, 1977). Recently, molecular signatures of metastatic potential are found within the bulk of primary tumors (Ramaswamy et al., 2003; van ’t Veer et al., 2002), suggesting that metastasis may be an intrinsic property inherited in the primary cancers.

Interestingly, the expressions of 3 out of 17 such signature genes were altered in the same directions in our model, indicating that the Pt en conditional knockout mice may provide a
unique tool to study the molecular mechanisms underlying prostate cancer metastasis. In fact, among 11 Pten conditional knockout mice age 12–29 weeks, 5 had lymphovascular invasion by the prostatic cancer cells. Distance metastases lesions were found in the lymph nodes and lung. Even though autopsy survey indicates possible metastatic foci in other organs, most of the metastasis lesions are very small and can be easily missed during histology sectioning. Thus, the actual rate of metastasis could be higher than what we have identified pathologically.

A unique property of prostate cancer is the frequently observed bone metastasis and subsequent osteoblastic/osteoclastic lesions (Bubendorf et al., 2000; Cher, 2001; Harada et al., 1992; Mundy, 2002). Even though we have not positively identified colonies of prostate cancer cells in bone metastases, we did observe dramatic bone remodeling activity in 3/11 aged Ptenlox/lox;Cre+ mice (data not shown). Our analyses also detected increased osteopontin expression levels (Supplemental Table S1, and Z. Song, personal communication), an event known to associate with the presence of bone metastasis in men with prostate cancer (Hotte et al., 2002; Thalmann et al., 1999). Further studies using sensitive imaging methodologies and more prostate-specific markers will help to address this issue.

Changes in gene expression profiling

From the top 100 most significantly regulated genes of our cDNA array analysis, we identified several genes that were well documented in the literature for participating prostate cancer initiation, progression, and metastasis.

One of the most interesting genes is Nkx3.1. Nkx3.1 is located in human chromosome 8p21, a region frequently deleted in human prostate cancer (He et al., 1997), and its inactivation has been shown to correlate with prostate cancer initiation and progression (Bowen et al., 2000). Interestingly, the mechanism of Nkx3.1 loss in Pten null prostate cancers may differ from the Myc transgenic model (Ellwood-Yen et al., 2003 [this issue of Cancer Cell]). Instead of gradual and cancer stage-dependent Nkx3.1 downregulation observed in the Myc model, we found that Nkx3.1 loss is directly correlated with PTEN loss and AKT activation. This correlation can be observed as earlier as 4 weeks, a pre-cancer stage (Supplemental Figure S1). Interestingly, some of the genes known to be regulated by NXX3.1 (Magee et al., 2003), such as probasin, are also downregulated in Pten null prostate cancers (Figure 6A). This result suggests that the mechanisms of Nkx3.1 loss of function in human prostate cancers may depend on the initial tumorigenic events. Indeed, synergistic effect of PTEN and NXX3.1 on tumor initiation has been reported (Kim et al., 2002).

PSCA is another molecule that we identified by microarray and confirmed to be upregulated in Pten null prostate cancer. PSCA is expressed in almost all cases of high-grade PIN and is overexpressed in 40% of local and as many as 100% of bone metastatic prostate cancers (Gu et al., 2000). Our array analysis demonstrated that the expression of PSCA is upregulated by 14-fold in Pten null adenocarcinoma, consistent with our previous report that the percentage and intensity of mPSCA-positive cells increases dramatically in Pten mutant prostate cancers (Dubey et al., 1999). Further experiments using sensitive imaging methodologies and more prostate-specific markers will help to address this issue.
**Pten prostate cancer model and androgen ablation therapy**

The seminal works conducted more than 60 years ago by Huggins et al. (1941) have addressed some of the most fundamental questions regarding the requirement of androgen for normal prostate cell as well as prostate cancer cell growth and survival (Denmeade and Isaacs, 2002). However, the molecular basis underlying the development of androgen-independent prostate cancer growth after androgen ablation therapy, or HRPC, has not been resolved to date.

What is the cellular origin of HRPC? The normal prostatic epithelium consists of at least three cell types, basal cells, secretory luminal cells, and neuroendocrine cells (Bui and Reiter, 1998; Isaacs, 1999). The secretory luminal cells are terminally differentiated and androgen dependent and will undergo atrophy and die upon androgen withdrawal. Neuroendocrine cells do not express androgen receptor (AR) and thus are androgen independent. Basal cells are generally considered to be androgen independent, although their progeny, the intermediate precursors, do express low levels of AR and are potentially androgen responsive. Therefore, HRPC could derive from (1) a subpopulation of androgen-independent tumor cells that is present before hormone ablation therapy (Isaacs, 1999) or (2) cells that gained androgen independency due to additional genetic alterations and selected out after castration (Craft et al., 1999). The Pten prostate cancer cells are AR positive and do respond to androgen ablation therapy. However, the Pten null cells remain proliferative after prolonged castration (Figure 4B). Thus, Pten deletion either renders prostate cancer cells to proliferate in the absence of androgen and/or mobilizes androgen-independent basal cells to enter cell cycle. Further studies, such as colocalizing Ki-67-positive cells with different prostatic cell-specific markers, will help in distinguishing these possibilities.

On the molecular level, it has been proposed that restoration of AR activity is critical for androgen-refractory prostate cancer cells, based on clinical findings that HRPC still expresses AR and androgen-regulated genes, such as prostate-specific antigen (PSA). Several recent studies suggest the presence of crosstalks between the PI3-kinase/Akt and AR signaling pathways. Unfortunately, the effects in different cell lines and from different labs often seem contradictory, leading to confusion in the field as to whether PI3K/Akt exerts a positive or negative effect on AR. For example, Manin et al. have claimed that the PI 3-kinase/Akt pathway is required for basal and dihydrotestosterone-induced AR expression in prostate cell lines (Manin et al., 2002); whereas Lin et al. have shown that AKT and Mdm2 form a complex with AR and promote phosphorylation-dependent AR ubiquitination, resulting in AR degradation by the proteasome (Lin et al., 2002). It is clear from our study that activation of PI3-kinase/AKT signaling pathway cannot prevent cell death caused by androgen ablation. Thus, if there is a crosstalk between AR and PI3-kinase/AKT pathways in vivo, the effects will not be significant in preventing androgen-sensitive cells from apoptosis. Consistent with this notion, a recent study suggested that FKHR/AR complex may play an important role in protection of prostate cancer cells from apoptosis through AKT-independent pathway (Li et al., 2003). Whether AKT activation will lead to androgen-independent cell proliferation, either mediated by AR or independent of AR, remains to be investigated.

**Experimental procedures**

**Generation of prostate-specific Pten exon 5 deletion Pten<sup>fl<sup>−/−</sup>C</sup> mice**

To generate Pten<sup>fl<sup>−/−</sup>C</sup> mice, ARR2Probasin-Cre transgenic line, PB-Cre4 (Wu et al., 2001) on C57BL/6xDBA2 background were crossed to Pten<sup>fl<sup>−/−</sup>C</sup> mice on a 129/Balb/c background. The males offspring with Pten<sup>fl<sup>−/−</sup>C</sup> genotype were then crossed to Pten<sup>−/−</sup> females. Only F2 generation of male offspring was used in this study.

**Histology and immunochemistry analysis**

Tissues were fixed in 10% buffered Formalin for 6–10 hr, followed by gentle wash and transfer to 70% alcohol. These paraffin-embedded tissues were sectioned (4 μm) and stained with hematoxylin & eosin. All IHC staining was performed on 4 μm sections that were prepared from paraffin-embedded blocks and placed on charged glass slides. Antigen retrieval was performed by incubating the slides in 0.01 M citric acid buffer (pH 6.0) at 95°C for 30 min. Slides were then allowed to cool for 20 min in citric acid buffer. After washing in deionized water, the slides were then transferred to PBS (pH 7.4) (2 × 5 min each). The endogenous peroxidase activity was inactivated in a solution containing 3% hydrogen peroxide (H₂O₂) in methanol. The following detection and visualization procedures were performed according to manufacturer’s protocol. Slides were counterstained in Mayer’s hematoxylin, dehydrated, cleared, and coverslipped. Negative control slides were run without primary antibody. Control slides known to be positive for each antibody were incorporated.

For AR (PG-21, Upstate Biotechnology) and Nkx3.1 (DE#2, a kind gift from Dr. Abate-Shen at the Center for Advanced Biotechnology and Medicine, Robert Wood Johnson Medical School) staining, pretreated sections were first blocked with 10% normal goat serum and then the primary antibodies were diluted as suggested by the manufacturer and incubated overnight at 4°C. Following three washes with PBS, the antigens were visualized using the biotin-streptavidin based detection system from BioGenex. For PTEN (26H9, Cell Signaling Technology) staining, pretreated sections were first blocked with mouse IgG blocking reagent in the VECTOR M.O.M. Immunodetection Kit (Vector Laboratories) and then incubated with primary antibody at room temperature for 30 min.

For fluorescence double staining, the section was treated as above and first stained with mouse antibody (PTEN) followed by signal amplification with TSA Plus Fluorescence Systems (PerkinElmer). After biotin blocking, the section was then stained with rabbit antibody (NKK3.1, P-AKT), and signal was amplified with TSA system with different fluorescence.

**Apoptosis and proliferation index**

Cells undergoing apoptosis were determined by TUNEL assay using the In Situ Cell Death Detection Kit from Roche according to manufacturer’s instruction. Sections were de-waxed with xylene and rehydrated through graded alcohol. DNA fragmentation was labeled with fluorescein-conjugated dUTP and visualized with converter-POD and DAB. Apoptotic cell was identified by positive TUNEL staining and the appearance of apoptotic body. Five hundred cells were counted from five different view fields, and the TUNEL-positive cells were presented as numbers per 100 nucleated cells. Cell proliferation index was determined by Ki67 staining and calculated as above except 100 nucleated cells were counted per view field.

**Microarray preparation**

Custom cDNA microarrays enhanced for genes expressed in the mouse prostate were prepared on poly-lysine-coated glass microscope slides using a robotic spotting tool as previously described (Aaltomaa et al., 1999). Each array consisted of 10290 unique mouse cDNAs, 4511 of which were derived from cDNA libraries of developing and mature mouse prostate (http://www.mpedb.org) (Nelson et al., 2002). The remaining 5779 cDNAs were chosen from the Research Genetics sequence-verified set of IMAGE clones (http://www.resgen.com/products/SVMcDNA.php3) and from the National Institute of Aging 15K set. The clone inserts were amplified by PCR, purified, and analyzed by gel electrophoresis. All PCR products were sequence-
verified prior to spotting. Additional control cDNAs were included, and some clones were spotted twice for a total of 11552 features on the array.

**Probe construction, microarray hybridization, and data acquisition**

The protocol used for indirect labeling of cDNAs was described previously (Pritchard et al., 2001). Briefly, cDNA probes that incorporate aminoethyl dUTP (aa-dUTP; Sigma-Aldrich) were made using 50 µg of total RNA. Purified cDNA from *Pten* null and age-matched wild-type prostates was labeled with either Cy3 or Cy5 monoreactive fluoros (Amersham Life Sciences), combined, and competitively hybridized to microarrays under a coverslip for 16 hr at 63°C. Fluorescent array images were collected for Cy3 and Cy5 emissions using a GenePix 4000B fluorescent scanner (Axon Instruments, Foster City, California). Image intensity data were extracted and analyzed using GenePix 4.0 microarray analysis software. RNA from four *Pten* null prostates and four age-matched wild-type prostates was analyzed using the microarray. Each experiment was performed in duplicate with reversal of the fluorescent label to account for dye effects.

**Data normalization and statistical analysis**

Log-ratios of PTEN/WT signal were normalized using a print tip-specific intensity-based scatter plot smoother that uses robust locally linear fits to capture the dependence of the log-ratios on overall log-spot intensities (Dudoit, 2000). Statistical Analysis of Microarrays (SAM) software was used to determine genes that showed statistically significant differences in *Pten* null mice (Tusher et al., 2001). At a delta of 2.36, 579 genes were significantly upregulated in *Pten* null prostates and 462 were downregulated. The median false discovery rate (FDR) was 0.085%, which predicts that ~1 of the 1041 differentially expressed genes is falsely discovered. The differentially expressed genes other than ESTs were clustered and visualized with the Cluster and TreeView program from Dr. Eisen’s laboratory, and the top 50 most significant were presented.

**Western blot analysis**

Extract was prepared by sonicating prostate tissues in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, 1 mM PMSF, and cocktail protease inhibitors (Roche). Seventy micrograms tissue lysate were subjected to SDS-PAGE followed by Western blot analysis using anti-PTEN (9552, cell signaling), phospho-Akt (9271, cell signaling), NKX3.1 (a kind gift by Dr. Abate-Shen), PSCA (a kind gift by Dr. Owen Witte from DeMarzo, A.M., Nelson, W.G., Isaacs, W.B., and...), and actin (A 4700, sigma) antibodies, respectively.

**Acknowledgments**

We thank Drs. Sawyers, Chow, Wu, Herschman, and Reiter and members of our laboratories for helpful comments; Drs. Ellwood and Sawyers for exchanging unpublished results; Dr. Robert Cardiff and Robert J. Munn for pathology analysis; Dr. Abate-Shen for anti-Nkx3.1 antibody; Drs. Reiter and Witte for anti-PSCA antibody; Dr. Lily Wu for AR immunohistochemistry; and Ms. Lawson for technical assistance. H.W. is an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). S.W and G.L. are supported by the grant from DOD: PC991538 and NIH CA98013. G.V.T. is supported by a grant from DOD: PC991538 and UCLA Prostate SPORE career Development grant. P.S.N. is supported in part by a Damon Runion scholar award. This work was partially supported by grants from NIH: CA98013, DOD: PC991538, and CapCure (to H.W.), and NIH CA 59705 (to P.R.-B.), and NIH DK65204 and DK59125 (to P.S.N.).

---

Received: April 22, 2003
Revised: July 27, 2003
Published: September 22, 2003

**References**


CANCER CELL : SEPTEMBER 2003 219


